Features | VJHemOnc

Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Top abstracts from the VJHemOnc Post-EHA Lymphoma Highlights webinar 2026

We have highlighted five key abstracts from the Post-EHA 2026 Lymphoma Highlights webinar with the potential to influence the management…

Top abstracts from the VJHemOnc Post-EHA AML Highlights webinar 2026

Read about five abstracts from the Post-EHA 2026 AML Highlights webinar that showcase advances in the treatment of acute myeloid…

Top abstracts from the VJHemOnc Post-EHA CLL Highlights webinar 2026

We summarize five abstracts from the Post-EHA 2026 CLL Highlights webinar that may influence future treatment strategies for chronic lymphocytic…

Top abstracts from the VJHemOnc Post-EHA MDS Highlights webinar

We have summarized five standout abstracts from the Post-EHA 2026 MDS Highlights webinar, showcasing advances that continue to shape MDS…

Top abstracts from the VJHemOnc Post-EHA MPN Highlights webinar 2026

Explore five abstracts from the Post-EHA 2026 MPN Highlights webinar that may influence future treatment strategies across myeloproliferative neoplasms (MPNs).

Top abstracts from the VJHemOnc Post-EHA Myeloma Highlights webinar 2026

We have highlighted five abstracts from the Post-EHA 2026 Myeloma Highlights webinar that may influence future treatment strategies across multiple…

FDA approves isatuximab subcutaneous formulation via OBI for multiple myeloma

On July 10, 2026, the U.S. Food and Drug Administration (FDA) granted approval to the isatuximab subcutaneous (SC) formulation administered…

FDA approves Orca-T, a novel allogeneic T-cell-based immunotherapy, for patients with hematological malignancies undergoing SCT

On June 30, 2026, the U.S. Food and Drug Administration (FDA) granted approval of Orca-T, an allogeneic T-cell-based immunotherapy, for…